Living Cell Technologies implant given regulatory tick in Russia
- 10 March, 2010 11:53
- Comments (2)
Xenotransplantation specialists Living Cell Technologies' (LCT) subsidiary, LCT Biomedical, has been given the tick by Russian regulators for its encapsulation device which is central to its Diabecell technology for the treatment of Type 1 diabetes.
Regulatory approval in Russia is significant because the Russian standard is accepted in other parts of Europe, said Dr Paul Tan, Chief Executive Officer LCT in a statement.
The encapsulation device can also be used for other delivery applications, including drug delivery and biologics.
LCT's Diabecell technology uses the device to implant insulin producing cells from a pig, thus obviating the need for insulin injections to treat Type 1 diabetes, and can do so without the need for immunosuppressant drugs. The technology is currently undergoing trials in New Zealand.
“In addition to LCT’s two lead products - DIABECELL for treatment of Type 1 diabetes and NTCELL for the treatment of Parkinson’s disease - there is already interest in Russia for the use of the capsules as a drug and biologic delivery system,” said Tan.
-
Dictionary of DNA and Genome Technology 2E
-
Molecular & Cell Biology for Dummies
-
An Introduction to Molecular Biotechnology - Molecular Fundamentals, Methods and Applications in Modern Biotechnology
-
The Scientific American a Day in the Life of Your Brain
-
Molecular Forensics
-
Introduction to Statistics for Forensic Scientists
-
Proteins - Structure and Function
-
Fluorescence Applications in Biotechnology and Life Sciences
-
Statistics for Terrified Biologists
Comments
Anonymous
skip the JDRF and donate directly, as the jdrf does not fund promising research such as this. LCT and their team of heroes deserve awards.
Anonymous
JDRF has lost their focus - have they given up hope?
You are right.
JDRF originally raised money for "the Cure" - but they've had very little success to date despite investing hundreds of millions of dollars. Largely because they fund small-minded, conservative approaches, rather than big picture lateral-thinking approaches (like LCT has adopted) which seek to leap beyond current medical thinking.
By being so conservative, JDRF have been steered into more and more short-term tangential targets. Their major focus is now increasingly on moving towards an "artificial pancreas" (without having established that it is even viable or practical) - but what happened to the cure???? They've sold out and are now just an adjunct to big pharma's efforts (and we all know how many diseases THEY've cured in the last 50 years!!).
Let's hope the LCT team under Bob Elliott make that breakthrough - without JDRF's help.
Post new comment